Sandbox Reserved 1650

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (15:36, 20 January 2022) (edit) (undo)
(PDBID and PDB link)
 
(21 intermediate revisions not shown.)
Line 5: Line 5:
'''Introduction'''
'''Introduction'''
-
[https://en.wikipedia.org/wiki/Thyroglobulin Human thyroglobulin (TG)] is a precursor of two [https://en.wikipedia.org/wiki/Thyroid_hormones thyroid hormones] (TH): tetraiodothyronine or [[thyroxine]] (T4) and [[triiodothyronine (T3)]], two thyroid hormones (TH). Its structure is essential for the diagnosis, treatment and monitoring of thyroid-related diseases.
+
[https://en.wikipedia.org/wiki/Thyroglobulin Human thyroglobulin (TG)] is a precursor of two [https://en.wikipedia.org/wiki/Thyroid_hormones thyroid hormones] (TH): tetraiodothyronine or [[thyroxine]] (T4) and [[triiodothyronine (T3)]], essential for '''growth''', '''development''' and the '''control of metabolism'''. Its structure is essential for the diagnosis, treatment and monitoring of thyroid-related diseases.
 +
'''PDBID''': 6scj.
-
== Synthesis <ref> https://doi.org/10.1016/0022-2836(87)90403-7</ref><ref>DOI 11581009</ref> <ref> https://doi.org/10.1111/j.1432-1033.1987.tb11466.x</ref><ref>DOI 11479128</ref><ref> https://doi.org/10.1016/0014-5793(82)80346-3</ref><ref>DOI 3016640</ref> ==
+
[https://www.rcsb.org/sequence/6SCJ/ See the complete sequence.]
-
=== Role and composition of the thyroid gland ===
+
-
The thyroid gland is an endocrine organ located in the neck that secretes thyroid hormones into the bloodstream. Among them, T4 and T3 are involved in the growth, development and regulation of the metabolism of vertebrates.
+
-
 
+
-
The thyroid gland is made up of thyroid vesicles, which are made up of thyroid follicular cells that are arranged around a lumen containing a viscous substance called colloid. The diet is a source of iodide I- ions which, once in the blood, are picked up by the thyroid cells and then partly discharged into the colloid.
+
-
 
+
-
=== Expression of the TG gene===
+
-
Thyroid follicular cells synthesize human <scene name='86/868183/Full_tg/2'>TG</scene> via the TG gene on chromosome 8.
+
== Composition and 3D structure <ref>DOI 32025030</ref> ==
== Composition and 3D structure <ref>DOI 32025030</ref> ==
-
=== Global structure and its acquisition ===
+
=== Global structure ===
-
Once synthesized, the acquisition of the 3D structure of the <scene name='86/868183/Full_tg/2'>TG</scene> [[https://www.youtube.com/watch?v=ZKZy3sVNYAo&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF>TG]] is enabled by the ER chaperone proteins of the thyroid follicular cells via a slow process <ref>DOI 10.1042/BJ20021257</ref>.
+
'''Human thyroglobulin''' is a dimeric glycoprotein (see a <scene name='86/868183/Monomer_tg/1'>monomer</scene>) consisting of 2 times '''2749 amino acid residues''' with a molecular weight of '''660 kDa'''. The average size of the dimer is '''120x235 Å'''.
-
+
-
The result is a dimeric glycoprotein consisting of 2749 amino acid residues with a molecular weight of 600 kDa. The average size of the dimer is 120x235 Å.
+
-
+
-
Each of its monomers comprises 5 distinct regions on which approximately 66 <scene name='86/868183/Tyr/2'>tyrosines</scene> (chain A in blue, chain B in green, chain C in dark red, chain D in light red) are distributed. These are the regions :
+
-
<scene name='86/868183/Ntd/4'>N-terminal domain</scene> [[https://www.youtube.com/watch?v=MuFHlCZCetU&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=5>NTD]], <scene name='86/868183/Core/3'>Core</scene> [[https://www.youtube.com/watch?v=Lx1G1KGxKN8&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=8>CORE]], <scene name='86/868183/Flap/2'>Flap</scene> [[https://www.youtube.com/watch?v=vk60Rdyo28A&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=6>FLAP]], <scene name='86/868183/Arm/2'>Arm</scene> [[https://www.youtube.com/watch?v=XzeTjQKfO0E&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=9>ARM]] and <scene name='86/868183/Ctd/2'>C-terminal domain</scene> [[https://www.youtube.com/watch?v=N-mg_xj-deI&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=7>CTD]].
+
-
In addition, <scene name='86/868183/Full_tg/2'>TG</scene> has about 120 <scene name='86/868183/Cysteine/1'>cysteine residues</scene> allowing the formation of about 60 disulfide bridge bonds per monomer [[https://www.youtube.com/watch?v=Nuryu1aSqvY&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=11>Disulfide bridge]]. It is therefore a very stable and soluble protein.
+
Each of its monomers comprises '''5 distinct regions''' on which approximately 66 <scene name='86/868183/Tyr/1'>tyrosines</scene> (chain A in blue, chain B in green, chain C in dark red, chain D in light red) are distributed. These are the regions :
 +
<scene name='86/868183/Ntd/6'>N-terminal domain (NTD)</scene> [[https://www.youtube.com/watch?v=MuFHlCZCetU&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=5>NTD]], <scene name='86/868183/Core/4'>Core</scene> [[https://www.youtube.com/watch?v=Lx1G1KGxKN8&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=8>CORE]], <scene name='86/868183/Flap/4'>Flap</scene> [[https://www.youtube.com/watch?v=vk60Rdyo28A&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=6>FLAP]], <scene name='86/868183/Arm/3'>Arm</scene> [[https://www.youtube.com/watch?v=XzeTjQKfO0E&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=9>ARM]] and <scene name='86/868183/Ctd/4'>C-Terminal Domain (CTD)</scene> [[https://www.youtube.com/watch?v=N-mg_xj-deI&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=7>CTD]].
-
=== Post-translational modifications ===
+
The <scene name='86/868183/Ctd/4'>carboxyl-terminal domain</scene> of TG (about 520 amino acids) shows homology with the [[Acetylcholinesterase]] and other esterases.
-
TG also undergoes N-glycosylations in the ER at 17 <scene name='86/868183/Carbohydrated/1'>glycosylation sites</scene>, so that 10% of its molecular weight is carbohydrate. These modifications enhance its stability and solubility. Indeed, the two monomers are linked not by covalent interactions but via numerous interactions allowed by these N-glycosylations.
+
 
 +
In addition, <scene name='86/868183/Tg/2'>TG</scene> has about 120 cysteine residues allowing the formation of about 60 <scene name='86/868183/Ssbonds/1'>disulfide bridge bonds</scene> per <scene name='86/868183/Monomer_tg/1'>monomer</scene> [[https://www.youtube.com/watch?v=Nuryu1aSqvY&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=11>Disulfide bridge]]. It confers great stability and solubility.
 +
 
 +
These enzymes belong to the class of α-β hydrolase fold superfamily, characterized by α–helices and β-strands that roughly alternate along the polypeptide chain.<ref name="jeso">DOI 26595189</ref>
=== Structure of hormonogenic sites ===
=== Structure of hormonogenic sites ===
-
Hormonogenic sites are responsible for the formation of one TH each. They are formed by 2 or even 3 tyrosines at less than 15 Å from each other, and exposed to the solvent. Of these tyrosines, 1 or 2 are acceptors and 1 is a donor.
+
'''Hormonogenic sites''' are substrates for TH formation. They are formed by 2 or even 3 tyrosines at less than 15 Å from each other, and exposed to the solvent. Of these tyrosines, 1 or 2 are acceptors and 1 is a donor.
-
There are 7 hormonogenic sites for <scene name='86/868183/Full_tg/2'>TG</scene> :
+
There are 4 hormonogenic sites for <scene name='86/868183/Tg/3'>TG</scene> :
-
- two <scene name='86/868183/Site_a/1'>A sites</scene>, comprising two fixed donor tyrosines Y234 and Y149 and one flexible acceptor tyrosine: T24 [[https://www.youtube.com/watch?v=98MKFRc6S_w&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=4>SIte A]]
+
- an <scene name='86/868183/Site_a/2'>A site</scene>, comprising two fixed donor tyrosines Y234 and Y149 and one flexible acceptor tyrosine: Y24 [[https://www.youtube.com/watch?v=98MKFRc6S_w&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=4>Site A]].
-
- two <scene name='86/868183/Site_b/3'>B sites</scene>, including one Y2573 donor and one Y2540 acceptor [[https://www.youtube.com/watch?v=aNd32NLk9Fk&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=3>Site B]]
+
- a <scene name='86/868183/Site_b/4'>B site</scene>, including one Y2573 donor and one Y2540 acceptor [[https://www.youtube.com/watch?v=aNd32NLk9Fk&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=3>Site B]].
-
- a C site, comprising both donor and acceptor tyrosine Y2766
+
- a '''C site''', comprising both donor and acceptor tyrosine Y2766 (not resolved in the map).
-
- two <scene name='86/868183/Sites_d/1'>D sites</scene>, comprising a Y108 donor and a Y1310 acceptor [[https://www.youtube.com/watch?v=JYUPk59lVVw&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=2>Site D]]
+
- a <scene name='86/868183/Site_d/1'>D site</scene>, comprising a Y108 donor and a Y1310 acceptor [[https://www.youtube.com/watch?v=JYUPk59lVVw&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF&index=2>Site D]].
An acidic Asp (aspartic acid) or Glu (glutamic acid) residue always precedes the acceptor and a lysine is always close to the donor.
An acidic Asp (aspartic acid) or Glu (glutamic acid) residue always precedes the acceptor and a lysine is always close to the donor.
Except for site C, donors are at the fixed regions of the dimer while acceptors are at the flexible regions.
Except for site C, donors are at the fixed regions of the dimer while acceptors are at the flexible regions.
 +
 +
== Synthesis<!-- <ref>PMID: 3681978</ref> <ref>DOI 11581009</ref> --><ref>DOI 11479128</ref><ref>PMID: 6895876</ref><ref>DOI 3016640</ref> and acquisition of its structure ==
 +
=== Role and composition of the thyroid gland ===
 +
 +
The [https://en.wikipedia.org/wiki/Thyroid/ thyroid] gland is an endocrine organ located in the neck that secretes thyroid hormones into the bloodstream. Among them, T4 and T3 are involved in the growth, development and regulation of the metabolism of vertebrates.
 +
 +
The [https://en.wikipedia.org/wiki/Thyroid/ thyroid] gland is made up of thyroid vesicles, which are made up of thyroid follicular cells that are arranged around a lumen containing a viscous substance called colloid. The diet is a source of iodide I- ions which, once in the blood, are picked up by the thyroid cells and then partly discharged into the colloid.
 +
 +
=== Expression of the TG gene===
 +
In humans, TG is coded by a large gene roughly '''300 kb long''', located on chromosome 8. The number of exons has been estimated to be around 48, each of which is separated by introns varying in size up to 64 kb. TG gene expression is controlled positively by '''thyro-tropin (TSH)''' through the modulation of the intra-cellular levels of '''cyclic adenosine monophosphate (cAMP)''' via its receptor (TSHr) located at the basal membrane of the cell.<ref>PMID: 11581009</ref>
 +
 +
=== Post-translational modifications ===
 +
TG also undergoes N-glycosylations in the [https://en.wikipedia.org/wiki/Endoplasmic_reticulum endoplasmic reticulum] at <scene name='86/868183/Glycosylation_sites/1'>17 glycosylation sites</scene>, so that 10% of its molecular weight is carbohydrate. TG also undergoes maturation steps in this organelle, where it acquires dilsufide-bonds. These modifications enhance its stability and solubility. Indeed, the two monomers are linked not by covalent interactions but via numerous interactions allowed by these N-glycosylations.
 +
 +
=== Folding ===
 +
Once synthesized, the acquisition of the 3D structure of the <scene name='86/868183/Full_tg/2'>TG</scene> [[https://www.youtube.com/watch?v=ZKZy3sVNYAo&list=PLMGnv0h7EIJydYifu7JSxrkXMzpwlkyDF>TG]] is enabled by the ER chaperone proteins of the thyroid follicular cells via a slow process <ref>DOI 10.1042/BJ20021257</ref>.
== Functions ==
== Functions ==
Line 52: Line 61:
Once their 3D structure is acquired, TGs are exported into the colloid by exocytosis thanks to their signal peptide which will be cleaved. This extracellular storage increases the amount of TG stored in the body.
Once their 3D structure is acquired, TGs are exported into the colloid by exocytosis thanks to their signal peptide which will be cleaved. This extracellular storage increases the amount of TG stored in the body.
-
In the colloid, about 30 tyrosines out of the 66 tyrosines, each consisting of a phenol group, are iodized. The quantity of iodinated tyrosine depends however on the iodide concentration of the colloid. Indeed, one or two iodide ions can be covalently bound to the colloid and thus give a di (DIT) or mono-iodinated (MIT) phenol group. The iodination of the phenol groups is carried out by two membrane enzymes of the follicular cells: the double oxidase (DUOX) synthesizes the hydrogen peroxide H2O2 necessary for thyroid peroxidase (TPO).
+
In the colloid, about '''30 tyrosines''' out of the '''66 tyrosines''', each consisting of a phenol group, are iodized. The quantity of iodinated tyrosine depends however on the iodide concentration of the colloid. Indeed, one or two iodide ions can be covalently bound to the colloid and thus give a '''di- (DIT)''' or '''mono-iodinated (MIT) phenol group'''. The iodination of the phenol groups is carried out by two membrane enzymes of the follicular cells: the double oxidase ('''DUOX''') synthesizes the hydrogen peroxide H2O2 necessary for thyroid peroxidase ('''TPO'''). The synthesis is completed by TG proteolysis.
-
Due to the spatial conformation of <scene name='86/868183/Full_tg/2'>TG</scene>, there is a transfer of di or mono iodinated aromatic ring from a donor tyrosine to a close acceptor diiodotyrosine for the 14 tyrosines of the hormonogenic sites. Acceptor iodinated tyrosines are DITs because they are deprotonated due to their 6.5 acid pka facilitating the acceptance reaction leading to the formation of quinol-ether bonds, whereas donor iodinated tyrosines are MITs with a pKa of 8.5<ref>DOI 10.1530/eje.0.1380227</ref>.
+
Due to the spatial conformation of <scene name='86/868183/Tg/3'>TG</scene>, there is a transfer of di- or mono-iodinated aromatic ring from a donor tyrosine to a close acceptor diiodotyrosine for the 14 tyrosines of the hormonogenic sites. Acceptor iodinated tyrosines are DITs because they are deprotonated due to their 6.5 acid pka facilitating the acceptance reaction leading to the formation of quinol-ether bonds, whereas donor iodinated tyrosines are MITs with a pKa of 8.5<ref>DOI 10.1530/eje.0.1380227</ref>.
At the end of the coupling, the donor tyrosines are left with a dehydroalanine.
At the end of the coupling, the donor tyrosines are left with a dehydroalanine.
-
Once iodization and coupling have been performed, endocytosis of the colloid to the lysosome occurs. The <scene name='86/868183/Full_tg/2'>TG</scene> is proteolyzed by cathepsin proteases<ref>DOI 1939080</ref> and 7 TH are thus released from 14 mono- or di iodinated tyrosines.
+
Once iodization and coupling have been performed, endocytosis of the colloid to the lysosome occurs. The <scene name='86/868183/Tg/3'>TG</scene> is proteolyzed by cathepsin proteases<ref>DOI 1939080</ref> and 7 TH are thus released from 14 mono- or di-iodinated tyrosines.
-
The hormone synthesis function of TG is thus particularly linked to its structure. Moreover, research shows that denaturation or a simple modification of its conformation prevents the formation of TH <ref>DOI 10.1016/0005-2795(73)90365-6</ref><ref>DOI 456595</ref>.
+
The hormone synthesis function of TG is thus particularly linked to its structure. Moreover, research shows that denaturation or a simple modification of its conformation prevents the formation of TH <ref>PMID:4710237</ref><ref>DOI 456595</ref>.
==== Control ====
==== Control ====
-
The synthesis of TH from TG is stimulated by thyroid stimulating hormone (TSH) secreted by the pituitary gland, a gland of the brain. When the TSH receptor is activated, glycosylations leading to the mono iodination of tyrosines promote the synthesis of T3<ref>DOI 3182849</ref><ref>DI 10.1016/S0021-9258(18)46037-1</ref>.
+
The synthesis of TH from TG is stimulated by thyroid stimulating hormone (TSH) secreted by the pituitary gland, a gland of the brain. When the TSH receptor is activated, glycosylations leading to the mono iodination of tyrosines promote the synthesis of T3<ref>DOI 3182849</ref><ref>PMID: 1370485</ref>.
On the other hand, if the amount of hormones is too high, a negative feedback is exerted on this process while a small amount of these hormones exerts a positive feedback.
On the other hand, if the amount of hormones is too high, a negative feedback is exerted on this process while a small amount of these hormones exerts a positive feedback.
=== Iodine tank ===
=== Iodine tank ===
-
The complex and particularly stable structure of <scene name='86/868183/Full_tg/2'>TG</scene> gives it iodide reservoir properties. Indeed, all iodinated but non-hormonoid tyrosines are useful for iodine storage in the thyroid gland.
+
The complex and particularly stable structure of <scene name='86/868183/Tg/3'>TG</scene> gives it iodide reservoir properties. Indeed, all iodinated but non-hormonoid tyrosines are useful for iodine storage in the thyroid gland.
-
== Interest in the medical field<ref>DOI 17614775</ref><ref>DOI 12721190</ref><ref>DOI 24147207</ref><ref>DOI 11788684</ref><ref>DOI 17201802</ref><ref>DOI 10.1677/ERC-10-0292</ref><ref>DOI 5773064</ref><ref>DOI 3681445</ref><ref>DOI 12089177</ref><ref>DOI 21134539</ref><ref>DOI 6814409</ref><ref>DOI 29984794</ref><ref>DOI 21649472</ref><ref>DOI 28593684</ref><ref>DOI 29246752</ref><ref>DOI : 10.1001/jama.1979.03290350043022</ref> ==
+
== Interest in the medical field<ref>DOI 6814409</ref><ref>DOI 29984794</ref><ref name="jeso"/> ==
-
=== Modification of the TG quantity related to the desease ===
+
=== Modification of the TG quantity related to the disease ===
-
A healthy subject has between 5 and 25 µg of TG per liter of blood. In case of thyroid dysfunction, this level may increase or decrease. For example, it decreases in the case of congenital athyreosis (insufficiency of the thyroid gland) or prior to a miscarriage due to the presence of anti-TG antibodies, but increases in the case of cancer, thyroiditis, inflammation of the thyroid or autoimmune thyroid diseases AITD (Grave's disease, Hashimoto's thyroiditis).
+
A healthy subject has between '''5 and 25 µg of TG per liter''' of blood.<ref>DOI 5773064</ref> In case of thyroid dysfunction, this level may increase or decrease. For example, it decreases in the case of congenital athyreosis (insufficiency of the thyroid gland) or prior to a miscarriage due to the presence of anti-TG antibodies, but increases in the case of cancer, thyroiditis, inflammation of the thyroid or autoimmune thyroid diseases '''AITD''' <ref>DOI 24147207</ref>(Grave's disease, Hashimoto's thyroiditis).<ref>DOI 11788684</ref><ref>DOI 17614775</ref>
-
In addition, a decrease in the size or capacity of the thyroid causes a decrease in the synthesis of TH by the <scene name='86/868183/Full_tg/2'>TG</scene>, and thus a drop in the blood level of T4 and T3, which in turn causes heart disease, brain disease and abnormalities in the development of the fetus.
+
In addition, a decrease in the size or capacity of the thyroid causes a decrease in the synthesis of TH by the <scene name='86/868183/Tg/3'>TG</scene>, and thus a drop in the blood level of T4 and T3, which in turn causes heart disease, brain disease and abnormalities in the development of the fetus. <ref>DOI 29246752</ref><ref>DOI 28593684</ref><ref>DOI 12721190</ref>
-
The variation of the quantity of TG can thus be as much a cause as a consequence of disease.
+
The variation of the quantity of TG can thus be as much a cause as a consequence of disease.<ref>DOI 17201802</ref>
-
=== Use of TG to treat deseases ===
+
=== Use of TG to treat diseases ===
-
A classic TSH-stimulated <scene name='86/868183/Full_tg/2'>TG</scene> measurement or ultrasensitive <scene name='86/868183/Full_tg/2'>TG</scene> measurement allows to control its rate in a more or less sensitive way and therefore to detect a disease like those mentioned above, to ensure the effectiveness of a treatment and the absence of recurrence and to avoid
+
A classic '''TSH-stimulated''' <scene name='86/868183/Tg/3'>TG</scene> measurement or ultrasensitive <scene name='86/868183/Tg/4'>TG</scene> measurement allows to control its rate in a more or less sensitive way and therefore to detect a disease like those mentioned above, to ensure the effectiveness of a treatment and the absence of recurrence and to avoid
-
miscarriages.
+
miscarriages.<ref>DOI 3681445</ref>
-
Since serum <scene name='86/868183/Full_tg/2'>TG</scene> levels are correlated with the volume of thyroid tissue, we can also estimate the mass of thyroid tissue to detect hyperthyroidism, a disease related to an enlarged thyroid or, conversely, hypothyroidism.
+
Since serum <scene name='86/868183/Tg/3'>TG</scene> levels are correlated with the volume of thyroid tissue, we can also estimate the mass of thyroid tissue to detect '''hyperthyroidism''', a disease related to an enlarged thyroid or, conversely, '''hypothyroidism'''.
-
For example, thyroidectomy and a iodine-131 therapy can be performed to cure thyroid cancer with an 80% chance. Following removal and iodine-131 therapy, thyroglobulin is this time produced by malignant thyrocytes. As a result, its blood level is indistinguishable from that of a healthy person.
+
For example, [https://en.wikipedia.org/wiki/Thyroidectomy thyroidectomy] and a iodine-131 therapy can be performed to cure thyroid cancer with an 80% chance. Following removal and iodine-131 therapy, thyroglobulin is this time produced by malignant thyrocytes. As a result, its blood level is indistinguishable from that of a healthy person. <ref>PMID: 762873</ref><ref>DOI 21649472</ref>
-
But in case of recurrence and persistence of cancer, its level can increase again. Thyroglobulin therefore always serves as a tumor marker allowing us to estimate the risk of recurrence (>2ng/ml) or persistence (>1ng/ml) or remission.
+
But in case of recurrence and persistence of cancer, its level can increase again. Thyroglobulin therefore always serves as a tumor marker allowing us to estimate the risk of recurrence (>2ng/ml) or persistence (>1ng/ml) or remission.<ref>DOI 10.1677/ERC-10-0292</ref>
 +
 
Line 92: Line 102:
== References ==
== References ==
<references/>
<references/>
-
<ref>DOI 26595189</ref>
 

Current revision

This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Human thyroglobulin (TG)

Human thyroglobulin

Drag the structure with the mouse to rotate

References

  1. Coscia F, Taler-Vercic A, Chang VT, Sinn L, O'Reilly FJ, Izore T, Renko M, Berger I, Rappsilber J, Turk D, Lowe J. The structure of human thyroglobulin. Nature. 2020 Feb 5. pii: 10.1038/s41586-020-1995-4. doi:, 10.1038/s41586-020-1995-4. PMID:32025030 doi:http://dx.doi.org/10.1038/s41586-020-1995-4
  2. 2.0 2.1 Di Jeso B, Arvan P. Thyroglobulin From Molecular and Cellular Biology to Clinical Endocrinology. Endocr Rev. 2016 Feb;37(1):2-36. doi: 10.1210/er.2015-1090. Epub 2015 Nov 23. PMID:26595189 doi:http://dx.doi.org/10.1210/er.2015-1090
  3. van de Graaf SA, Ris-Stalpers C, Pauws E, Mendive FM, Targovnik HM, de Vijlder JJ. Up to date with human thyroglobulin. J Endocrinol. 2001 Aug;170(2):307-21. doi: 10.1677/joe.0.1700307. PMID:11479128 doi:http://dx.doi.org/10.1677/joe.0.1700307
  4. Brocas H, Christophe D, Pohl V, Vassart G. Cloning of human thyroglobulin complementary DNA. FEBS Lett. 1982 Jan 25;137(2):189-92. doi: 10.1016/0014-5793(82)80346-3. PMID:6895876 doi:http://dx.doi.org/10.1016/0014-5793(82)80346-3
  5. Baas F, van Ommen GJ, Bikker H, Arnberg AC, de Vijlder JJ. The human thyroglobulin gene is over 300 kb long and contains introns of up to 64 kb. Nucleic Acids Res. 1986 Jul 11;14(13):5171-86. doi: 10.1093/nar/14.13.5171. PMID:3016640 doi:http://dx.doi.org/10.1093/nar/14.13.5171
  6. Mendive FM, Rivolta CM, Moya CM, Vassart G, Targovnik HM. Genomic organization of the human thyroglobulin gene: the complete intron-exon structure. Eur J Endocrinol. 2001 Oct;145(4):485-96. doi: 10.1530/eje.0.1450485. PMID:11581009 doi:http://dx.doi.org/10.1530/eje.0.1450485
  7. Di Jeso B, Ulianich L, Pacifico F, Leonardi A, Vito P, Consiglio E, Formisano S, Arvan P. Folding of thyroglobulin in the calnexin/calreticulin pathway and its alteration by loss of Ca2+ from the endoplasmic reticulum. Biochem J. 2003 Mar 1;370(Pt 2):449-58. doi: 10.1042/BJ20021257. PMID:12401114 doi:http://dx.doi.org/10.1042/BJ20021257
  8. de Vijlder JJ, den Hartog MT. Anionic iodotyrosine residues are required for iodothyronine synthesis. Eur J Endocrinol. 1998 Feb;138(2):227-31. doi: 10.1530/eje.0.1380227. PMID:9506870 doi:http://dx.doi.org/10.1530/eje.0.1380227
  9. Dunn AD, Crutchfield HE, Dunn JT. Thyroglobulin processing by thyroidal proteases. Major sites of cleavage by cathepsins B, D, and L. J Biol Chem. 1991 Oct 25;266(30):20198-204. PMID:1939080
  10. Rolland M, Montfort MF, Lissitzky S. Efficiency of thyroglobulin as a thyroid hormone-forming protein. Biochim Biophys Acta. 1973 Apr 20;303(2):338-47. doi:, 10.1016/0005-2795(73)90365-6. PMID:4710237 doi:http://dx.doi.org/10.1016/0005-2795(73)90365-6
  11. Maurizis JC, Marriq C, Michelot J, Rolland M, Lissitzky S. Thyroid peroxidase-induced thyroid hormone synthesis in relation to thyroglobulin structure. FEBS Lett. 1979 Jun 1;102(1):82-6. doi: 10.1016/0014-5793(79)80933-3. PMID:456595 doi:http://dx.doi.org/10.1016/0014-5793(79)80933-3
  12. Fassler CA, Dunn JT, Anderson PC, Fox JW, Dunn AD, Hite LA, Moore RC, Kim PS. Thyrotropin alters the utilization of thyroglobulin's hormonogenic sites. J Biol Chem. 1988 Nov 25;263(33):17366-71. PMID:3182849
  13. Di Jeso B, Liguoro D, Ferranti P, Marinaccio M, Acquaviva R, Formisano S, Consiglio E. Modulation of the carbohydrate moiety of thyroglobulin by thyrotropin and calcium in Fisher rat thyroid line-5 cells. J Biol Chem. 1992 Jan 25;267(3):1938-44. PMID:1370485
  14. Galligan JP, Winship J, van Doorn T, Mortimer RH. A comparison of serum thyroglobulin measurements and whole body 131I scanning in the management of treated differentiated thyroid carcinoma. Aust N Z J Med. 1982 Aug;12(4):248-54. doi: 10.1111/j.1445-5994.1982.tb03805.x. PMID:6814409 doi:http://dx.doi.org/10.1111/j.1445-5994.1982.tb03805.x
  15. Flores-Rebollar A, Perez-Diaz I, Lagunas-Barcenas S, Garcia-Martinez B, Rivera-Moscoso R, Fagundo-Sierra R. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk? Acta Otorhinolaryngol Ital. 2018 Jun;38(3):188-193. doi: 10.14639/0392-100X-1494. PMID:29984794 doi:http://dx.doi.org/10.14639/0392-100X-1494
  16. Torrigiani G, Doniach D, Roitt IM. Serum thyroglobulin levels in healthy subjects and in patients with thyroid disease. J Clin Endocrinol Metab. 1969 Mar;29(3):305-14. doi: 10.1210/jcem-29-3-305. PMID:5773064 doi:http://dx.doi.org/10.1210/jcem-29-3-305
  17. Kawasaki E, Yasui J, Tsurumaru M, Takashima H, Ikeoka T, Mori F, Akazawa S, Ueki I, Kobayashi M, Kuwahara H, Abiru N, Yamasaki H, Kawakami A. Sequential elevation of autoantibodies to thyroglobulin and glutamic acid decarboxylase in type 1 diabetes. World J Diabetes. 2013 Oct 15;4(5):227-30. doi: 10.4239/wjd.v4.i5.227. PMID:24147207 doi:http://dx.doi.org/10.4239/wjd.v4.i5.227
  18. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF. Thyroglobulin is a thyroid specific gene for the familial autoimmune thyroid diseases. J Clin Endocrinol Metab. 2002 Jan;87(1):404-7. doi: 10.1210/jcem.87.1.8291. PMID:11788684 doi:http://dx.doi.org/10.1210/jcem.87.1.8291
  19. Leboeuf R, Emerick LE, Martorella AJ, Tuttle RM. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. Thyroid. 2007 Jun;17(6):543-7. doi: 10.1089/thy.2007.0020. PMID:17614775 doi:http://dx.doi.org/10.1089/thy.2007.0020
  20. De Leo S, Pearce EN. Autoimmune thyroid disease during pregnancy. Lancet Diabetes Endocrinol. 2018 Jul;6(7):575-586. doi:, 10.1016/S2213-8587(17)30402-3. Epub 2017 Dec 12. PMID:29246752 doi:http://dx.doi.org/10.1016/S2213-8587(17)30402-3
  21. Katko M, Gazso AA, Hircsu I, Bhattoa HP, Molnar Z, Kovacs B, Andrasi D, Aranyosi J, Makai R, Veress L, Torok O, Bodor M, Samson L, Nagy EV. Thyroglobulin level at week 16 of pregnancy is superior to urinary iodine concentration in revealing preconceptual and first trimester iodine supply. Matern Child Nutr. 2018 Jan;14(1). doi: 10.1111/mcn.12470. Epub 2017 Jun 7. PMID:28593684 doi:http://dx.doi.org/10.1111/mcn.12470
  22. Matalon ST, Blank M, Levy Y, Carp HJ, Arad A, Burek L, Grunebaum E, Sherer Y, Ornoy A, Refetoff S, Weiss RE, Rose NR, Shoenfeld Y. The pathogenic role of anti-thyroglobulin antibody on pregnancy: evidence from an active immunization model in mice. Hum Reprod. 2003 May;18(5):1094-9. doi: 10.1093/humrep/deg210. PMID:12721190 doi:http://dx.doi.org/10.1093/humrep/deg210
  23. Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romijn JA, Smit JW. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2007 Jan;66(1):58-64. doi:, 10.1111/j.1365-2265.2006.02685.x. PMID:17201802 doi:http://dx.doi.org/10.1111/j.1365-2265.2006.02685.x
  24. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987 Dec;28(12):1888-91. PMID:3681445
  25. Gerfo PL, Colacchio T, Colacchio D, Feind C. Thyroglobulin in benign and malignant thyroid disease. JAMA. 1979 Mar 2;241(9):923-4. PMID:762873
  26. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H, Tomoda C, Yabuta T, Masuoka H. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011 Jul;21(7):707-16. doi: 10.1089/thy.2010.0355. Epub 2011 Jun 7. PMID:21649472 doi:http://dx.doi.org/10.1089/thy.2010.0355
  27. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer. 2011 Mar 3;18(2):R29-40. doi: 10.1677/ERC-10-0292. Print, 2011 Apr. PMID:21183629 doi:http://dx.doi.org/10.1677/ERC-10-0292
Personal tools